Parkinsons Disease News: Breaking Parkinsons Disease News, Comments and Articles.

Merck hit with Phase III failure for Parkinson's drug

Merck & Co is discontinuing development of its adenosine A2a receptor antagonist, preladenant, for Parkinson's disease (PD) after an initial review of data from three separate Phase III trials failed to provide evidence of efficacy for.....

Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures

Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.

New animal model gives insights into mechanisms of Parkinson's disease pathogenesis

In Parkinson's disease, the protein "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of the brain become progressively affected as the disease develops and advances. The mechanism underlying this pathological progression is...

Scientists identify molecular trigger for Alzheimer’s disease

Researchers have pinpointed a catalytic trigger for the onset of Alzheimer’s disease – when the fundamental structure of a protein molecule changes to cause a chain reaction that leads to the death of neurons in the brain. For the first time, scientists at Cambridge’s Department of Chemistry have been able to map in detail the pathway that generates “aberrant” forms o...

Proteins in migration: New animal model provides important clues on mechanisms of Parkinson's disease

Scientists have developed a novel experimental model that reproduces for the first time this pattern of alpha-synuclein brain spreading and provides important clues on the mechanisms underlying this pathological process. They triggered the production...

Merck & Co drops development of PD candidate preladenant

Following review of three separate Phase III studies of preladenant, US pharma giant Merck & Co (NYSE: MRK) said that these did not provide evidence of efficacy for this investigational adenosine A2A receptor antagonist in the treatment of Parkinson'...

Heptares Augments Business Development Capabilities in Japan and Other Asian Territories

WELWYN GARDEN CITY, England and BOSTON, May 24, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, is pleased to announce that it has engaged Mr Akira Usui as a Consultant to augment the Company's business development capabilities in Japan and other Asian territories. Mr Usui has more than 15 years of experience in business development, licensing...

Merck updates on preladenant clinical program for treatment of Parkinson's disease

Merck, known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease.

Pharmaceutical Research: Angiopep-Conjugated Nanoparticles for Targeted Long-Term Gene Therapy of Parkinson’s Disease

Type: Original PaperPurposeTo prepare an angiopep-conjugated dendrigraft poly-L-lysine (DGL)-based gene delivery system and evaluate the neuroprotective effects in the rotenone-induced chronic model of Parkinson’s disease (PD).MethodsAngiopep was a...

Nutritional Supplement Delays Advancement Of Parkinson's And Familial Dysautonomia

Widely available in pharmacies and health stores, phosphatidylserine is a natural food supplement produced from beef, oysters, and soy. Proven to improve cognition and slow memory loss, it's a popular treatment for older people experiencing memory im...

Proteins in migration

(Helmholtz Association of German Research Centres) Scientists at the German Center for Neurodegenerative Diseases in Bonn have developed a new animal model that provides important clues on the mechanisms of Parkinson's disease. The research team head...

Merck pulls plug on Parkinson's drug

Merck pulls plug on Parkinson's drug

Merck halts development of experimental Parkinson's drug

May 23 (Reuters) - Merck & Co has ended development of preladenant, an experimental drug for Parkinson's disease, after initial data from three late-stage trials proved disappointing.

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment of Parkinson’s disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladena...

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Merck discontinues preladenant for PD

Merck & Co. Inc. (NYSE:MRK) said it no longer plans to submit regulatory applications for preladenant to treat Parkinson's disease after an initial review of data from three double-blind Phase III trials "did not provide evidence of efficacy" for the...

NDI Launches Deep Brain Innovations, LLC

Optimizing electrical stimulation to treat Parkinson's disease and other neurological conditions. Cleveland, OH and Durham, NC (PRWEB) May 23, 2013 NDI Medical, LLC, a venture and commercialization firm that funds and develops innovative neurodevice technologies, has launched its next portfolio company, Deep Brain Innovations, LLC (DBI). DBI will commercialize its groundbreaking technology t...

Merck provides update on Phase III clinical program for preladenant

Merck provides update on Phase III clinical program for preladenant, the company’s investigational parkinson’s disease medicine...

CannaMed Now Offering Boston Medical Cards: Medical Marijuana Card

CannaMed is now offering Medical Marijuana Consultations in Boston (Framingham). Boston, MA (PRWEB) May 23, 2013 CannaMed is now offering Medical Marijuana Consultations in Boston (Framingham). As per The Initiative Petition for a Law for the Humanitarian Medical Use of Marijuana that passed pursuant to Amendment Article 48 of the Massachusetts Constitution. CannaMed is one of only a few Medical...

At-risk women 'underestimate likelihood of fractures'

Postmenopausal women with conditions such as Parkinson's disease and multiple sclerosis (MS) tend to underestimate their risk of fractures, a study suggests.The bone-thinning disease osteoporosis mainly affects women following the menopause, greatly increasing their chances of fracturing a bone.Women with some neurological conditions, rheumatoid arthritis or a history of stroke are at least tw...

Cynapsus Therapeutics Reports First Quarter 2013 Financial Results and Recent Developments

TORONTO, ONTARIO -- (Marketwired) -- 05/23/13 -- Cynapsus Therapeutics Inc. (TSX VENTURE: CTH), developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the three months ended March 31, 2013. Unless specified otherwise, all amounts are in Ca...

Defective cellular waste removal explains why Gaucher patients often develop Parkinson's disease

(Cell Press) Gaucher disease causes debilitating and sometimes fatal neurodegeneration in early childhood. New research published online on May 23 in Cell Metabolism indicates that the neurodegeneration found in Gaucher disease stems from defects in...

13th Annual National Meniere's Disease & Trigeminal Neuralgia Symposium, 10 a.m., Saturday, June 22, 2012

Meniere's Disease & Trigeminal Neuralgia Breakthrough; a Story of Survival! Learn about important traditional & complementary alternatives to one-sided neurological problems. Grand Rapids, MI (PRWEB) May 22, 2013 The featured speaker at this year’s Meniere's Disease Research Institute's Workshop is Dr. Michael T. Burcon, world's leading expert on Meniere's disease (M...

10 Warning Signs: What Your Mouth Says About Your Health

NEW YORK, May 22, 2013 /PRNewswire/ -- If the eyes are the windows to your soul, then your mouth is the gateway to your overall health.  Research has found a surprising number of links between the state of your dental health and your overall health.  (Photo: http://photos.prnewswire.com/prnh/20130522/NY18272 ) Be on the lookout for these warning signs provided for you by Marc Lie...

Impax Hires Specialists to Help Sort Manufacturing Issues

Faced with manufacturing quality questions that caused the FDA to reject its potential Parkinson’s disease treatment, Impax Laboratories has hired a committee of specialists to oversee quality improvements at its California facility.